Briacell Presents Clinical Data From Pivotal Phase 3 Study Of Bria-IMT, In Metastatic Breast Cancer Supporting Use Of Specific Biomarkers To Predict Patients' Clinical Response To Bria-IMT Treatments

• Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study
• Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits
• Positive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free survival (PFS) in Phase 3 patients
• Presence of Circulating Tumor Cells (CTC) after patients' initial Phase 3 treatment supports role as negative prognostic marker (p = 0.04)
• Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile

PHILADELPHIA and VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting clinical data from the pivotal Phase 3 study of its lead product candidate, Bria-IMT™, in metastatic breast cancer (BRIA-ABC; NCT06072612) supporting the use of specific biomarkers to predict patients' clinical response to Bria-IMT treatments.